Bridgewater, N.J.-based Amneal Pharmaceuticals is the latest company to recall its ranitidine products after discovering they contain unacceptable levels of a possible carcinogen.
Amneal is recalling more than 90 lots of its 150 mg and 300 mg ranitidine tablets and of its 15 mg ranitidine syrup to the consumer level after finding potential amounts of N-Nitrosodimethylamine above FDA standards.
The same carcinogen has prompted global recalls of ranitidine products, used to treat heartburn.
Amneal has not received any reports of adverse events related to the recall.
The lots of the recalled products were distributed directly to wholesalers, distributors, retailers and repackagers. Anyone with the recalled lots should quarantine them immediately.
The company also warned consumers to stop using the recalled products.
Read the full news release here.